merger agreement

Powerus appoints retired Rear Admiral Jamie Sands III to advisory board, bolstering leadership ahead of 2026 Nasdaq merger with Aureus Greenway Holdings.

$SBEV received NYSE delisting notice for failing equity requirements; pursuing Medterra CBD merger to restore compliance by January 2027.

Ligand Pharmaceuticals to acquire XOMA Royalty for $39/share in $739M cash deal, expanding portfolio and raising 2026 EPS guidance.

$UCB acquiring Peach State Bancshares for $100.8M in stock-cash deal, expected to close Q3 2026 with $0.09-$0.12 EPS accretion.

Talen Energy prices $4 billion in senior notes to finance 2,451 MW generation capacity acquisition and debt redemption.

Galera and Obsidian merge in all-stock deal with $350M financing, creating Obsidian Therapeutics ($OBX) focused on TIL cell therapies with funding through 2028.

Powerus, Aureus Greenway's merger target, raised $50M from Seoul-based KCGI to expand autonomous defense manufacturing in U.S. and South Korea.

SRx Health Solutions surged 5.69% in March 2026 via its EMJX AI engine, outpacing S&P 500's 4.98% decline. Board considers quarterly dividend policy based on portfolio profits.

Brink's expands credit facility to $3.85B to fund NCR Atleos acquisition, subject to regulatory and shareholder approvals.

Brink's expanded credit facility to $3.85B from $2.225B to fund planned $6.6B acquisition of NCR Atleos, pending regulatory approval.

SRx Health Solutions hedges DeFi exposure with gold investment, reduces emerging market hedge ahead of EMJ Crypto Technologies merger closing.

Independent Bank ($IBCP) to acquire HCB Financial ($HCBN) for $70.2M in cash-stock deal, creating $6.1B asset combined entity.

SRx Health Solutions implements hedging strategy for cryptocurrency and emerging market positions while advancing merger with EMJ Crypto Technologies.

SRx Health Solutions implements hedging strategy on cryptocurrency and emerging markets holdings while advancing merger with EMJ Crypto Technologies.

Agero to acquire Urgently for $5.50/share in all-cash deal, combining roadside assistance leaders serving 150M+ vehicles, with closure expected by May 2026.

Lisata Therapeutics agreed to be acquired by Kuva Labs for $5.00 per share plus up to $1.00 contingent payment, closing expected in Q2 2026.

Lisata Therapeutics agrees to be acquired by Kuva Labs for $5 per share plus up to $1 contingent payment tied to FDA approval, with close expected in Q2 2026.

Servier acquires Day One Biopharmaceuticals for $2.5B in cash, expanding rare pediatric oncology portfolio with closing expected Q2 2026.

Law firm investigates Mister Car Wash's take-private transaction at $7 per share for potential fiduciary duty violations by board and controlling shareholder.

Alcon's acquisition of LENSAR receives FTC Second Request, extending review. Companies expect deal to close in first half 2026 pending regulatory approval.